Abstract
N(6)-methyladenosine (m(6)A) is a ubiquitous RNA modification in mammals. This modification is "written" by methyltransferases and then "read" by m(6)A-binding proteins, followed by a series of regulation, such as alternative splicing, translation, RNA stability, and RNA translocation. At last, the modification is "erased" by demethylases. m(6)A modification is essential for normal physiological processes in mammals and is also a very important epigenetic modification in the development of cancer. In recent years, cancer-related m(6)A regulation has been widely studied, and various mechanisms of m(6)A regulation in cancer have also been recognized. In this review, we summarize the changes of m(6)A modification in prostate cancer and discuss the effect of m(6)A regulation on prostate cancer progression, aiming to profile the potential relevance between m(6)A regulation and prostate cancer development. Intensive studies on m(6)A regulation in prostate cancer may uncover the potential role of m(6)A methylation in the cancer diagnosis and cancer therapy.